BioAge Labs (NASDAQ:BIOA) Posts Earnings Results, Beats Expectations By $0.07 EPS

BioAge Labs (NASDAQ:BIOA) announced its quarterly earnings results on Wednesday. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07, Zacks reports. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.

BioAge Labs Price Performance

Shares of NASDAQ BIOA traded down $0.22 during mid-day trading on Wednesday, reaching $10.98. 1,127,982 shares of the company traded hands, compared to its average volume of 713,051. BioAge Labs has a fifty-two week low of $4.25 and a fifty-two week high of $25.95. The firm has a market cap of $488.09 million, a PE ratio of -4.57 and a beta of 0.94. The stock has a fifty day simple moving average of $20.39 and a 200-day simple moving average of $19.37.

Hedge Funds Weigh In On BioAge Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after buying an additional 93,694 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in BioAge Labs during the fourth quarter worth about $13,892,000. Geode Capital Management LLC raised its position in BioAge Labs by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after acquiring an additional 28,646 shares in the last quarter. State Street Corp lifted its holdings in BioAge Labs by 113.4% in the 4th quarter. State Street Corp now owns 422,846 shares of the company’s stock valued at $5,594,000 after acquiring an additional 224,735 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in BioAge Labs in the 4th quarter valued at about $5,406,000.

Analyst Upgrades and Downgrades

BIOA has been the subject of a number of recent research reports. Needham & Company LLC lowered their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Roth Capital restated a “buy” rating and set a $25.00 price target on shares of BioAge Labs in a research report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Finally, Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.57.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.